# A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

> **NCT00861510** · PHASE1 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 16 (actual)

## Conditions studied

- Lymphoma, Mantle-cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Hairy Cell
- Waldenstrom Macroglobulinemia
- Multiple Myeloma

## Interventions

- **DRUG:** ON01910 Na

## Key facts

- **NCT ID:** NCT00861510
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-05
- **Primary completion:** 2012-10-19
- **Final completion:** 2012-10-19
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861510, "A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00861510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*